Latest Advances

  • Condition: Early-Stage Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer
  • Journal: Zhonghua wai ke za zhi [Chinese journal of surgery]
  • Treatment Used: Docetaxel, Carboplatin plus Trastuzumab Regimen
  • Number of Patients: 522
  • Published —
The aim of the study was to examine the effectiveness of docetaxel, carboplatin plus trastuzumab regimen (TCH) in early-stage human epidermal growth factor receptor 2 (HER2) positive breast cancer.
  • Condition: Breast Cancer Brain Metastases
  • Journal: BMC cancer
  • Treatment Used: Trastuzumab Emtansin with Stereotactic Radiation
  • Number of Patients: 16
  • Published —
In this study, researchers evaluated the safety and effectiveness of trastuzumab emtansin with stereotactic radiation for the treatment of HER2+ breast cancer brain metastases.
  • Condition: HER2-Positive Early Breast Cancer
  • Journal: The Lancet. Oncology
  • Treatment Used: Pertuzumab and Trastuzumab Subcutaneous Injection plus Chemotherapy
  • Number of Patients: 500
  • Published —
The study compared the outcomes between pertuzumab and trastuzumab subcutaneous injection plus chemotherapy for treating HER2-positive early breast cancer.
  • Condition: HER2-Positive Relapsed Breast Cancer Previously Treated with Taxanes, Anthracyclines, and Trastuzumab
  • Journal: Annals of palliative medicine
  • Treatment Used: Pyrotinib Combined with Carboplatin
  • Number of Patients: 1
  • Published —
This case report describes a patient with HER2-positive relapsed breast cancer who had acquired resistance to trastuzumab treated with three cycles of treatments of pyrotinib (400 mg, orally once per day, days 1-21) combined with carboplatin (600 mg, iv drip, day 1, cycled every 21 days).
  • Condition: HER2 Positive Breast Cancer
  • Journal: Technology in cancer research & treatment
  • Treatment Used: Tyrosine Kinase Inhibitors in the Combination Therapy
  • Number of Patients: 0
  • Published —
The study researched the safety and effectiveness of tyrosine kinase inhibitors in the combination therapy for HER2 positive breast cancer.
  • Condition: Metastatic HER2(+) Breast Cancer
  • Journal: BMC cancer
  • Treatment Used: Biosimilar BCD-022
  • Number of Patients: 225
  • Published —
This study assessed the safety and effectiveness of BCD-022 and reference trastuzumab in combination with paclitaxel in the treatment of metastatic HER2(+) breast cancer.
  • Condition: Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer
  • Journal: Scientific reports
  • Treatment Used: Neoadjuvant Chemotherapy
  • Number of Patients: 1097
  • Published —
This study investigated the correlation between neutrophil-to-lymphocyte ratio (NLR) and pathologic complete response (pCR) and survival outcomes in patients with human epidermal growth factor receptor 2 (HER2)-negative breast cancer who were treated with neoadjuvant chemotherapy.
  • Condition: Cervical Lymphadenopathy and Dermal Involvement in Patient with Recurrent Breast Cancer
  • Journal: Journal of investigative medicine high impact case reports
  • Treatment Used: Xeloda Oral, Trastuzumab, and Pertuzumab Combined Drug Therapy
  • Number of Patients: 1
  • Published —
This case report describes a 42-year-old woman diagnosed with recurrent breast cancer with supraclavicular lymphadenopathy and dermal involvement treated with 6 cycles (1 per month) of trastuzumab subcutaneous 600 mg, pertuzumab intravenous 840 mg (as an attack dose, later on 420 mg), and xeloda oral 1000 mg.
  • Condition: Early HER2-Positive Breast Cancer in South Africa
  • Journal: South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde
  • Treatment Used: Adjuvant Trastuzumab
  • Number of Patients: 0
  • Published —
This article explored data on the use of trastuzumab for the treatment of early HER2-positive breast cancer in South Africa.
  • Condition: Metastatic Breast Cancer
  • Journal: Scientific reports
  • Treatment Used: Physical Activity
  • Number of Patients: 833
  • Published —
The study researched the outcomes of physical activity in patients with metastatic breast cancer.
Showing 1-12 of 109